United States Allergic Conjunctivitis Market Size, Share, and COVID-19 Impact Analysis, By Type (Giant, Atopic, Seasonal, Perennial, and Vernal), By Application (Epinastine, Mast Cell Stabilizers, Anti-histamines, Immunotherapy, and Others), and US Allergic Conjunctivitis Market Insights, Industry Trend, Forecasts to 2035

United States Allergic Conjunctivitis Market Insights Forecasts to 2035

• The USA Allergic Conjunctivitis Market Size was Estimated at USD 0.60 Billion in 2024
• The Market Size is Expected to Grow at a CAGR of around 6.42% from 2025 to 2035
• The US Allergic Conjunctivitis Market Size is Expected to reach USD 1.19 Billion by 2035

According to a research report published by Spherical Insights & Consulting, the USA Allergic Conjunctivitis Market is predicted to reach USD 1.19 billion by 2035, growing at a CAGR of 6.42% from 2025 to 2035. The market growth is attributed to the increasing prevalence of allergic conjunctivitis and exposure to allergens.

Market Overview  

The United States allergic conjunctivitis market is categorized under the healthcare sector, which involves diagnosis, treatment, and management of inflammatory eye conditions caused by allergens among the populations suffering from allergic conjunctivitis in the United States. The prevalence of allergic conjunctivitis, a common, mostly benign, and underappreciated condition, has risen during the last ten years. Genetics, inflammation, pollen exposure, air pollution, atopy, and pet contact are some of the causes. Conjunctival edema, redness, tearing, and itching are some of the symptoms that define the condition. It may cause a decline in vision and develop into keratoconjunctivitis. The course of treatment includes topical antihistamine eye drops, local cold compress treatment, saline eyedrops, and avoiding the allergen. Ocular itching is the primary symptom. A bilateral, self-limiting inflammatory process of the conjunctiva, allergic conjunctivitis, affects as many as the US population.

The rising cases of allergic conjunctivitis among the US population escalate the need for the diagnosis and treatment of allergic conjunctivitis, leading to the growth of the market. For instance, the data published in the Journal, Taylor and Francis, states that allergic conjunctivitis is an eye disorder causing mast cell degranulation, releasing histamine, cytokines, and inflammatory cells, with a 40% prevalence in the United States.

Report Coverage

This research report categorizes the market for the US allergic conjunctivitis market based on various segments and regions and forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the US allergic conjunctivitis market. Recent market developments and competitive strategies such as expansion, product launch, development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the US allergic conjunctivitis market.

Driving Factors

Innovations in the R&D sector and development in allergic conjunctivitis drugs:

Urbanization, industrialization, and an increase in allergens have all contributed to the rise in the prevalence of ocular allergies. To create efficient treatments for this conjunctivitis, biopharmaceutical companies are spending money on research and development. It is anticipated that these initiatives will propel market expansion. Drug bioavailability is limited by the anatomy of the eye, which raises interest in novel drug delivery systems. Another treatment option is the use of contact lenses to administer the over-the-counter antihistamine/mast cell inhibitor ketotifen. The market is expanding as a result of improvements in therapeutics for allergic conjunctivitis, which provide more patient-friendly and efficient treatment options. In recent years, antihistamines, mast cell stabilizers, and corticosteroids have all combined in precise drug formulations to reduce inflammation more quickly and for longer periods. Clinical practice and market dynamics are changing as a result of improved clinical trial methodologies, personalized and immunotherapeutic approaches, and advanced drug delivery systems. The market for allergic conjunctivitis in the United States is expanding due to rising patient demand brought on by improved clinical results and the introduction of new products.

Growing awareness of allergic rhinitis through campaigns:

Growing awareness of ocular allergies, primarily as a result of digital health campaigns, is driving the market for allergic conjunctivitis. Social media, medical websites, and smartphone apps make it simple to find information about symptoms, triggers, and available treatments. Through a focus on early diagnosis and preventive measures, groups such as the Allergy & Asthma Network and the American Academy of Ophthalmology support educational initiatives. Medication access has increased due to the convenience of online pharmacy platforms, and pharmaceutical companies are investing in online patient engagement strategies. It is anticipated that the demand for efficient treatments will increase as digital education is incorporated into healthcare.

Restraining Factors

The side effects associated with the eyedrops used for the management of allergic conjunctivitis, stringent regulatory approvals, limited awareness of the ocular allergy and its therapeutics in middle-income countries, and high cost of the treatment may impede the growth of the market.

Market Segmentation

The US allergic conjunctivitis market share is classified into type and application.

• The seasonal segment dominated the US allergic conjunctivitis market in 2024 and is expected to grow at a significant CAGR during the forecast period.

The US allergic conjunctivitis market is segmented by type into giant, atopic, seasonal, perennial, and vernal. Among these, the seasonal segment dominated the US allergic conjunctivitis market in 2024 and is expected to grow at a significant CAGR during the forecast period. The segmental growth is attributed to the increasing prevalence of allergic conjunctivitis during the seasonal climatic alterations like rainy season, airborne allergens, windy weather conditions, disease history of allergic rhinitis or asthma, urbanization, and air pollution.

• The antihistamines segment accounted for the largest share in 2024 and is expected to grow at a significant CAGR during the forecast period.

The USA allergic conjunctivitis market is segmented by application into epinastine, mast cell stabilizers, anti-histamines, immunotherapy, and others. Among these, the antihistamines segment accounted for the largest share in 2024 and is expected to grow at a significant CAGR during the forecast period. The extensive usage of antihistamines by the geriatric and pediatric population, selling of antihistamines as over-the-counter drugs, minimizes the symptoms of the conjunctivitis, is a first-line treatment of the allergic conjunctivitis, and is effective against conjunctivitis in all types of population.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the US allergic conjunctivitis market, along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Vanda Pharmaceuticals
• Marinomed Biotech AG
• W. Pharmaceuticals
• Aldeyra Therapeutics
• Bausch and Lomb Incorporated
• Noveome Biotherapeutics
• IACTA Pharmaceuticals
• Allakos, Inc.
• Eleusis Holdings Ltd.
• Regeneron Pharmaceuticals
• Others

Recent Developments:

• In May 2025, Aldeyra Therapeutics, Inc., a biotechnology company, achieved the primary endpoint in a Phase 3 randomized, double-masked, vehicle-controlled dry eye chamber trial of 0.25% reproxalap ophthalmic solution, an investigational new drug candidate for treating dry eye disease. The drug was significantly superior to the vehicle in reducing ocular discomfort symptom scores from 80 to 100 minutes after chamber entry.

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Market Segment

This study forecasts revenue at the United States, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the US allergic conjunctivitis market based on the below-mentioned segments:

US Allergic Conjunctivitis Market, By Type

• Giant
• Atopic
• Seasonal
• Perennial
• Verna

US Allergic Conjunctivitis Market, By Application

• Epinastine
• Mast Cell Stabilizers
• Anti-histamines
• Immunotherapy
• Others